Indication includes adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia, for LDL-C ...

Consideration includes $6.75/share upfront cash and up to $2.50/share CVRs, implying ~$3.8B total value and ~40% premium to the 30‑day VWAP. BPL‑003 (intranasal mebufotenin benzoate/5‑MeO‑DMT) targets ...

Kp-104 (vensobafusp alfa) advances as a Phase II/III-ready bifunctional complement biologic targeting alternative and terminal pathways, with rare renal Phase II basket interim reads in Q4 2026 and Q2 ...

Modern biopharma firms are adapting their R&D investment strategies in response to challenges such as the impending $300 ...

Pharmaceutical Executive recently spoke with Nuvation Bio’s president, CEO, and founder David Hung. The growing biotech is ...

It is also why I have spent over fifteen years building around a conviction the healthcare industry still resists: when ...

Sanofi Chief Digital Officer Emmanuel Frenehard on scaling AI across a Big Pharma global enterprise and why a strategy of ...

Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences ...

LillyDirect exemplifies DTP as a demand-unlocking commercial channel rather than a compliance tactic, with executives ...

Approval is backed by VIKTORIA-1 (PIK3CA wild-type), a global open-label randomized trial of gedatolisib plus fulvestrant ± palbociclib after progression on CDK4/6 therapy and an aromatase inhibitor.

A cGMP-related CRL can delay approval despite substantial efficacy/safety evidence and often requires manufacturing remediation and reinspection rather than additional clinical trials. Phase III CARES ...